Want to see CING full AI Analyst Report?
Top Page
Cingulate Inc
(NASDAQ:CING)
Select Model
Select Model
Rating:46Neutral
Price Target:
$4.50
▼(-15.41% Downside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by weak financial performance (no revenue, sustained losses, consistent cash burn, and elevated uncertainty from unusual TTM figures). Technicals provide a modest offset with mild positive momentum and price above key moving averages. Corporate events are mixed, with IP/index inclusion positives outweighed by an FDA delay risk and added dilution potential; valuation remains challenged due to ongoing losses and no dividend support.
Positive Factors
Proprietary Drug Delivery
The proprietary delivery approach is intended to improve how ADHD medicines release over the day, supporting once-daily dosing. If clinical development succeeds, this platform could differentiate Cingulate’s candidates and provide a repeatable foundation for addressing ADHD and related disorders.
Negative Factors
No Revenue and Ongoing Losses
Cingulate has not yet generated product revenue and continues to report operating and net losses, consistent with a pre-commercial biotech. This leaves financial progress dependent on successful clinical development and future funding rather than internally generated earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Drug Delivery
The proprietary delivery approach is intended to improve how ADHD medicines release over the day, supporting once-daily dosing. If clinical development succeeds, this platform could differentiate Cingulate’s candidates and provide a repeatable foundation for addressing ADHD and related disorders.
Read all positive factors
Cingulate Inc (CING) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$76.34M
Dividend YieldN/A
Average Volume (3M)100.53K
Price to Earnings (P/E)―
Beta (1Y)0.29
Revenue GrowthN/A
EPS Growth37.29%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.01
Shares Outstanding14,541,826
10 Day Avg. Volume125,907
30 Day Avg. Volume100,527
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.40
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.02
Forecast
1Y Price Target
$20.33Price Target Upside282.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.13
Revenue Forecast (FY)N/A
Cingulate Inc Business Overview & Revenue Model
Company Description
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx...
Cingulate Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
22
Negative
Cash Flow
8
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -24.79M | -19.40M | -14.99M | -22.18M | -17.11M | -19.97M |
| Net Income | -28.80M | -22.45M | -16.56M | -23.53M | -17.68M | -20.71M |
Balance Sheet | ||||||
| Total Assets | 33.07M | 15.07M | 14.86M | 3.49M | 11.41M | 22.89M |
| Cash, Cash Equivalents and Short-Term Investments | 28.40M | 10.95M | 12.21M | 52.42K | 5.36M | 16.49M |
| Total Debt | 6.29M | 8.79M | 5.10M | 3.51M | 5.87M | 1.18M |
| Total Liabilities | 9.60M | 12.56M | 7.41M | 10.36M | 7.52M | 2.04M |
| Stockholders Equity | 23.47M | 2.51M | 7.46M | -6.87M | 3.88M | 20.84M |
Cash Flow | ||||||
| Free Cash Flow | -20.94M | -17.41M | -18.66M | -15.26M | -16.04M | -11.25M |
| Operating Cash Flow | -20.65M | -17.25M | -18.45M | -15.03M | -15.88M | -10.43M |
| Investing Cash Flow | -284.48K | -162.00K | -211.80K | -224.10K | -152.65K | -814.74K |
| Financing Cash Flow | 40.44M | 16.15M | 30.82M | 9.95M | 4.90M | 26.54M |
Cingulate Inc Technical Analysis
Positive
5.32
Price Trends
5.03
Positive
4.98
Positive
5.44
Negative
Market Momentum
0.04
Negative
60.04
Neutral
85.17
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CING, the sentiment is Positive. The current price of 5.32 is above the 20-day moving average (MA) of 4.79, above the 50-day MA of 5.03, and below the 200-day MA of 5.44, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 60.04 is Neutral, neither overbought nor oversold. The STOCH value of 85.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CING.
Cingulate Inc Risk Analysis
Cingulate Inc disclosed 82 risk factors in its most recent earnings report. Cingulate Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cingulate Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $76.71M | -0.95 | -70.14% | ― | ― | 16.04% | |
46 Neutral | $76.34M | -1.05 | -238.41% | ― | ― | 37.29% | |
45 Neutral | $57.28M | -1.14 | 214.97% | ― | -31.12% | -35.10% | |
44 Neutral | $55.10M | -0.60 | -53.22% | ― | ― | 55.84% | |
42 Neutral | $50.12M | -0.87 | -1266.43% | ― | ― | 49.43% |
* Healthcare Sector Average
CING
Cingulate Inc
5.25
1.69
47.47%
MNOV
Medicinova
1.47
0.29
24.58%
CLNN
Clene
4.03
-5.10
-55.88%
PLRX
Pliant Therapeutics
0.89
-0.85
-48.91%
ELTX
Elicio Therapeutics
1.85
-7.55
-80.32%
ACRV
Acrivon Therapeutics, Inc.
1.79
-0.10
-5.29%
Cingulate Inc Corporate Events
Business Operations and StrategyExecutive/Board Changes
Cingulate Extends Trial Period for Chief Medical Officer
Neutral
Oct 2, 2026
On September 30, 2026, Cingulate Therapeutics LLC amended the employment agreement with Executive Vice President and Chief Medical Officer Matthew N. Brams, effective January 1, 2026. The amendment extended the trial period for his full-time emplo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.